Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Observational, Open-Label, Single-Arm Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Next Previous
X
Search
Trial Profile

A Multicenter, Observational, Open-Label, Single-Arm Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Nov 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms STRIVE
  • Sponsors Biogen

    • Most Recent Events

    • 13 Oct 2023 Results assessing the effect of natalizumab on CGM and thalamic atrophy over 2 years (from MRI scans of NTZ-treated (n=94) patients from the STRIVE study) compared with a historical placebo in patients (n=63) with early relapsing remitting multiple sclerosis (from the dimethyl fumarate DEFINE trial), presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis.
    • 26 Mar 2023 Results of post hoc analysis assessing the effectiveness and safety of natalizumab in patients who self-identified as either Black/African American (AA) or Hispanic/Latino, published in the Neurology and Therapy.
    • 05 Sep 2022 Results assessing effects of natalizumab on cognitive processing speed, confirmed disability improvement (CDI), and patient-reported outcomes , published in the CNS Drugs.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top